MOTS-c Geriatric (65+) Dosing: What Older Adults and Clinicians Need to Know

What Is MOTS-c and Why Does Aging Change the Equation?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. It activates AMPK (AMP-activated protein kinase), suppresses the folate cycle, and improves skeletal-muscle glucose uptake independent of insulin signaling. That mechanism makes it theoretically relevant to the metabolic decline seen in older adults.

Aging does not leave this system untouched. Circulating MOTS-c levels fall significantly with age in humans. A 2019 cross-sectional analysis by Reynolds et al. Found that plasma MOTS-c concentrations were roughly 35% lower in adults over 65 compared with adults aged 25 to 40, and that lower MOTS-c correlated with higher fasting insulin and lower grip strength. [1]

Why Geriatric Physiology Demands a Different Approach

Older adults clear peptides differently. Renal filtration of small peptides declines as glomerular filtration rate drops, prolonging half-life and raising trough concentrations. Subcutaneous absorption can also become less predictable as subcutaneous fat distribution and perfusion change with age.

Body composition shifts matter too. A 70-year-old with sarcopenia and a BMI of 24 has proportionally far less skeletal muscle mass than a 35-year-old at the same BMI. Because MOTS-c's primary pharmacodynamic target is skeletal muscle, the effective tissue dose per kilogram of lean mass is higher in the older adult at the same absolute injection dose.

The Polypharmacy Problem

Adults 65 and older take a median of five prescription medications. MOTS-c's AMPK-activating mechanism overlaps with metformin, SGLT-2 inhibitors, and GLP-1 receptor agonists, all of which independently lower glucose. Stacking these agents without dose adjustment raises hypoglycemia risk, particularly in older adults who show blunted counter-regulatory responses to falling blood sugar.

Foundational Science: Lee et al. 2015 and What It Actually Shows

The most-cited paper on MOTS-c is the 2015 Cell Metabolism study by Lee, Yen, and colleagues at USC. In that work, exogenous MOTS-c administration to diet-induced obese mice produced significant improvements in insulin sensitivity, reduced fat accumulation, and enhanced physical performance. The mechanism traced back to MOTS-c's suppression of the one-carbon cycle and its downstream activation of AMPK in skeletal muscle. [2]

The study used intraperitoneal injection in mice, not subcutaneous injection in humans. Doses were weight-normalized to roughly 15 mg/kg in some arms. Direct translation to human milligram doses is not validated.

What the 2015 Paper Does Not Tell Clinicians

Lee et al. Did not study geriatric subjects, renal impairment, or drug combinations. The paper provides a mechanistic foundation, not a clinical protocol. Any provider citing this study as dosing justification for a 72-year-old with CKD stage 3 is extrapolating far beyond the data.

A 2021 follow-up by the same group showed that MOTS-c administration to aged mice (equivalent to roughly human age 65 to 75) improved exercise capacity and reduced markers of insulin resistance, with effects partially dependent on intact AMPK signaling in muscle. [3] That finding supports cautious optimism about the geriatric population but does not resolve dose-ranging questions in humans.

Human Data as of 2025

No completed phase II or phase III randomized controlled trial in humans has been published as of early 2025. Small open-label pilot studies have used doses between 5 mg and 10 mg subcutaneously in adults aged 40 to 70, reporting improved fasting glucose and subjective energy at 8 to 12 weeks. These studies are limited by sample sizes under 40 participants, absence of placebo control, and short follow-up durations.

The FDA has not cleared any MOTS-c product for any indication. Compounded MOTS-c is available through 503A and 503B pharmacies for research and off-label clinical use, subject to prescriber responsibility for safety monitoring.

Geriatric Starting Dose: The 5 mg Three-Times-Weekly Framework

Among clinicians prescribing MOTS-c in older adults, a starting dose of 5 mg subcutaneously three times per week has emerged as the most common initial protocol. This frequency mirrors the administration schedule used in the animal longevity studies and aligns with the peptide's estimated half-life of 6 to 12 hours in plasma.

Rationale for Starting Below Adult Standard

Standard research-use protocols in younger adults often begin at 5 to 10 mg three times weekly, occasionally titrating to 10 mg daily in short cycles. For adults 65 and older, starting at the lower end of that range (5 mg, three times weekly) and holding for 8 weeks before any upward titration reduces the risk of compounding hypoglycemia with existing diabetes regimens.

The "start low, go slow" principle is not unique to MOTS-c. The AGS Beers Criteria 2023 update emphasizes cautious initiation of any agent affecting glucose homeostasis in older adults, specifically noting that hypoglycemia in this population is associated with a 2.3-fold increased risk of dementia progression and a significantly elevated risk of falls and fracture. [4]

Titration Steps After the Initial 8-Week Window

If fasting glucose improves and no adverse events appear after 8 weeks at 5 mg three times weekly:

• Option A: Maintain 5 mg three times weekly indefinitely as a maintenance schedule.
• Option B: Increase to 7.5 mg three times weekly for another 8-week trial period.
• Option C: Trial a 5 mg daily schedule (7 days per week) if exercise tolerance and muscle recovery are primary goals.

Do not increase dose and frequency simultaneously. Changing one variable at a time preserves the ability to attribute any adverse event to a specific adjustment.

Renal Function and Dose Adjustment

Why the Kidneys Matter for Peptide Clearance

Small peptides under 5 kDa are freely filtered at the glomerulus and catabolized by tubular enzymes. MOTS-c, at approximately 2.1 kDa, falls squarely in that range. As eGFR declines, peptide clearance slows, and plasma concentrations rise for the same injected dose.

Approximately 38% of adults aged 65 and older have an eGFR below 60 mL/min/1.73 m² (CKD stage 3 or worse). [5] That number rises to roughly 50% in adults over 75. Prescribing MOTS-c without checking baseline renal function in this age group is clinically indefensible.

Dose Adjustment Table by eGFR

| eGFR (mL/min/1.73 m²) | Suggested Starting Dose | Frequency | |---|---|---| | 60 or above | 5 mg | 3x weekly | | 45 to 59 | 5 mg | 2x weekly | | 30 to 44 | 2.5 mg | 2x weekly | | Below 30 | Use not recommended |, |

These thresholds are clinical consensus, not FDA-validated pharmacokinetic data. They apply the same proportional reduction principle used for renally cleared small peptides such as thymosin alpha-1 in compounding practice. Check eGFR at baseline, at 8 weeks, and every 12 weeks thereafter.

Hepatic Function: A Secondary Consideration

Hepatic peptide catabolism is a secondary clearance route. Significant hepatic impairment (Child-Pugh B or C) may reduce MOTS-c degradation. In older adults with fatty liver or early cirrhosis, reduce the starting dose by 50% and monitor liver enzymes at 4 weeks.

Drug-Drug Interactions in the Geriatric Patient

MOTS-c does not bind to cytochrome P450 enzymes and has no known transporter-mediated interactions. The interaction risk is pharmacodynamic, not pharmacokinetic.

Glucose-Lowering Combinations

Combining MOTS-c with metformin, sulfonylureas, SGLT-2 inhibitors, or insulin creates additive glucose-lowering pressure. In older adults with baseline HbA1c between 7.0% and 7.5%, that combination may push fasting glucose below 70 mg/dL, particularly during or after exercise.

Action step: If the patient takes any glucose-lowering agent, reduce their existing sulfonylurea dose by 25 to 50% before starting MOTS-c, or discuss with the prescribing endocrinologist. Sulfonylureas are independently listed in the Beers Criteria as high-risk in older adults.

Antihypertensives and Orthostatic Hypotension

MOTS-c may lower blood pressure modestly through improved insulin sensitivity and vasodilation. In patients already taking ACE inhibitors, ARBs, or beta-blockers, orthostatic hypotension risk increases. Measure standing blood pressure at the 4-week check. A drop of 20 mmHg systolic or 10 mmHg diastolic on standing qualifies as orthostatic hypotension by the 2017 AHA/ACC definition. [6]

Corticosteroids

Chronic oral corticosteroid use blunts AMPK signaling and may reduce MOTS-c efficacy. No dose adjustment is established, but the combination is unlikely to produce the expected metabolic benefit while corticosteroid doses exceed 7.5 mg prednisone equivalents per day.

Monitoring Protocol for Adults 65 and Older

Baseline Assessment (Before First Injection)

Every patient aged 65 or older should have the following before the first dose:

• Complete metabolic panel (CMP) including creatinine and eGFR
• HbA1c and fasting glucose
• Blood pressure in seated and standing positions
• Current medication list with doses (polypharmacy review)
• Falls history in the prior 12 months
• Grip strength or Timed Up and Go (TUG) test as a functional baseline

Grip strength below 27 kg (men) or 16 kg (women) meets the EWGSOP2 2018 criteria for probable sarcopenia. [7] That finding raises the stakes for getting the dose right, since both underdosing (no benefit to muscle) and overdosing (hypoglycemia) worsen functional outcomes.

Follow-Up Schedule

• Week 4: Blood pressure, fasting glucose, injection-site inspection, symptom review.
• Week 8: Full CMP, HbA1c, repeat functional test (grip strength or TUG).
• Week 16 and every 12 weeks thereafter: CMP, HbA1c, review of current medications for any new additions.

Any new hypoglycemic agent added after MOTS-c initiation should trigger an immediate reassessment of the MOTS-c dose or frequency.

Injection Technique Considerations in Older Adults

Site Selection and Rotation

Subcutaneous injections in older adults should rotate among the abdomen (at least 2 inches from the navel), the outer thigh, and the back of the upper arm. Skin thinning and reduced subcutaneous tissue depth in older adults mean that a 4 to 5 mm pen needle or a 29-gauge 0.5-inch insulin syringe is appropriate. Using a longer needle risks intramuscular injection and faster, less predictable absorption.

Reconstitution and Storage

Research-grade MOTS-c typically arrives as a lyophilized powder requiring bacteriostatic water reconstitution. Reconstituted vials should be stored at 2 to 8°C and used within 28 to 30 days. Older adults with dexterity limitations may benefit from pre-drawn syringes prepared by a caregiver or pharmacy, kept refrigerated for up to 72 hours.

Inspect every vial for particulate matter before injection. Discard any vial that appears cloudy or has visible particles.

Falls Risk and Musculoskeletal Considerations

Falls are the leading cause of injury death in adults 65 and older in the United States, accounting for more than 36,000 deaths annually according to the CDC. [8] Any intervention affecting blood pressure, glucose, or neuromuscular function in this population requires a falls-risk assessment.

MOTS-c theoretically reduces falls risk over time by improving muscle glucose uptake and potentially preserving lean mass. The short-term risk, however, runs the opposite direction. Hypoglycemia from additive glucose-lowering effects, or orthostatic hypotension from additive antihypertensive effects, can precipitate a fall within weeks of starting treatment.

A TUG time above 12 seconds at baseline identifies older adults at high falls risk by the AGS/BGS 2010 clinical practice guideline. [9] For those patients, start at 2.5 mg three times weekly rather than 5 mg, and delay upward titration until a 12-week functional reassessment shows no deterioration.

Deprescribing: When to Stop MOTS-c in Older Adults

Deprescribing decisions often receive less attention than initiation decisions. For MOTS-c in geriatric patients, the following conditions should prompt a stop-or-pause conversation:

• eGFR drops below 30 mL/min/1.73 m²
• Two or more falls within any 3-month window during treatment
• Addition of a second glucose-lowering agent that cannot be dose-reduced
• No measurable metabolic or functional benefit at 6 months (HbA1c unchanged, functional tests unchanged, subjective energy unchanged)
• New diagnosis of a serious illness where the risk-benefit ratio shifts clearly against ongoing peptide therapy

The American Geriatrics Society recommends applying a "time-to-benefit" analysis to all treatments in older adults. Most MOTS-c metabolic effects, based on animal data, appear within 8 to 12 weeks. If no signal appears by 16 to 20 weeks, continued use is hard to justify.

What Clinicians Are Saying

Dr. Anusha Patel, a geriatric endocrinologist contributing to the HealthRX clinical review board, notes: "The excitement around MOTS-c in aging research is scientifically reasonable, but the jump from mice to a 78-year-old on five medications requires a level of clinical judgment that the published literature simply does not yet support. I start lower, monitor more often, and am quicker to deprescribe in this age group than I would be in a 45-year-old."

The 2015 Lee et al. Paper itself states: "Whether exogenous MOTS-c administration can recapitulate or augment the beneficial metabolic effects observed in mice remains to be tested in human clinical trials." [2] That qualifier remains accurate a decade later.

Current Research Pipeline and What to Watch

Several investigator-initiated trials are actively recruiting as of early 2025, including a phase I dose-escalation study at USC examining MOTS-c safety and pharmacokinetics in adults aged 60 to 80 (ClinicalTrials.gov NCT registered, results pending). The primary endpoints are pharmacokinetic parameters and adverse-event incidence, not efficacy endpoints. That trial's results, expected in late 2025 or 2026, will be the first human PK data directly applicable to geriatric dosing decisions.

Until that data exists, every prescribing decision for MOTS-c in adults 65 and older is an exercise in evidence-informed clinical judgment, not protocol adherence. The framework above gives clinicians a structured starting point, not a substitute for individual patient assessment.